ScripMultiple major Chinese vaccine manufacturers are expecting annual profits to have slumped in 2024, as fiercer competition, destocking at vaccination clinics and a slowing Chinese economy all weigh on
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Zhifei Commits To Acquiring $2.93bn Of
ScripWho: UCB/CBC Group/Mubadala What: UCB is divesting some mature neurology and allergy products in China, as well as a manufacturing site in that country, to CBC and Mubadala. Why: UCB said the tra
Pink SheetMerck & Co. ’s HPV vaccine Gardasil appears headed into a sales slump in China, and the country’s ongoing crackdown on corruption in healthcare could be a factor in the decline. Gardasil is the firm’s